Physician profile
Gavin M Leask
NPI 1548227804
$15,818.39
in general payments reported to CMS, 2019-2025
40 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,997 · 2020: $927 · 2021: $1,400 · 2022: $3,962 · 2023: $2,283 · 2024: $2,938 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,283 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,282.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5,921.95 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $2,744.52 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $712.37 | 2019-2025 | |
| Pfizer INC. | $671.33 | 2019-2025 | |
| Biotronik INC. | $475.85 | 2019-2023 | Biomonitor |
| Astrazeneca Pharmaceuticals LP | $471.05 | 2019-2024 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $467.49 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $345.31 | 2019-2023 | Xarelto |
| Medtronic, INC. | $338.76 | 2021-2025 | Cobalt Dr Mri Surescan |
| Amgen INC. | $320.14 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $317.79 | 2019-2024 | Watchman Flx, Bodyguardian |
| Galderma Laboratories, L.P. | $317.56 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $300.56 | 2019-2025 | Camzyos, Eliquis |
| Vital Connect, INC | $280.61 | 2023-2024 | Vitalpatch Rtm |
| Philips North America LLC | $264.52 | 2023-2024 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Leask listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.